-
Article | 2020.06.22
A zebrafish model to study SARS-CoV-2 neuroinvasion
Aim: Invasion of the central nervous system, possibly via the olfactory nerve, is suspected to play a role in respiratory failure of Covid-19 patients. This project aims to test SARS-CoV- 2 neuroinvasiveness in vivo in a zebrafish model. The zebrafish larva allows easy visualization of the entire nervous system in vivo or with whole mount fixed samples. It could provide a cheap, genetically...
-
News | 2021.03.24
World Tuberculosis Day: ERA4TB accelerating the development of new treatment regimens
ERA4TB (the European Regimen Accelerator for Tuberculosis) is a 6-year public-private partnership with a total budget of over €200M that began in 2020 with the goal of accelerating the development of new treatment regimens for tuberculosis (TB). As part of the Innovative Medicines Initiative, ERA4TB brings together experts from academia and pharma, led by Stewart Cole (Institut Pasteur) and David...
-
Document de presse | 2022.12.13
Epidemics, pandemics: a never-ending story? – a look back at the conference held on December 7, 2022
In connection with the bicentenary of Louis Pasteur’s birth, a conference entitled "Epidemics, pandemics: a never-ending story?" was held on Wednesday December 7 at the Institut Pasteur under the high patronage of the French President, Emmanuel Macron. The conference marked the end of a year of events highlighting not only the importance of research in tackling infectious diseases, but also the...
-
News | 2022.12.07
SpikImm receives a major funding to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-CoV-2
SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Institut Pasteur, has been awarded a €15 million non-dilutive financing from the French governmentFrance 2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy. SPK001, the first treatment candidate (...
-
Document de presse | 2022.12.14
SARS-CoV-2: improving treatment for patients with a severe infection
Inflammatory responses to SARS-CoV-2 vary hugely from one individual to the next. Physicians and scientists from the Institut Pasteur, St. James's Hospital in Dublin and Trinity College Dublin have identified factors of increased vulnerability to COVID-19 in some people, which could guide the development of new therapeutic strategies. In particular, the scientists discovered a link between severe...
-
News | 2022.02.23
What is long COVID ?
In May 2020, while the first wave of the COVID-19 outbreak was coming to an end in France, initial reports emerged of patients with some persistent symptoms several weeks or months post-infection. This phenomenon, now referred to as "long COVID" (or post-COVID-19 syndrome) affects over 20% of patients after 5 weeks and over 10% of patients after 3 months. Serious or severe forms of initial SARS-...
-
News | 2020.10.22
Coronavirus: Institut Pasteur warns against false information circulating on social media
-ENGLISH VERSION COMING SOON-Mis à jour le 20 mars 2023.En 2020-2021, lorsque la pandémie de Covid-19 était à son pic, de nombreuses informations circulaient dans les médias, sur les réseaux sociaux, les messageries instantanées, etc. Ces messages ont pu parfois contenir des informations erronées ou s’appuyant sur des propos attribués à tort à des chercheurs de l’Institut Pasteur à...
-
Fiche maladie | 2018.12.05
Cystic fibrosis
Cystic fibrosis is the most common severe hereditary genetic disease in the Caucasian population. It is an autosomal recessive inherited disease of the CFTR gene. This fatal condition is characterized by respiratory impairment that affects approximately one in every 2,500 births in Europe and North America. Although the life expectancy of affected individuals has risen considerably since the...
-
News | 2020.07.03
Existing drugs can prevent SARS-CoV-2 from hijacking cells
Researchers evaluate how the new coronavirus rewires human proteins for its own replication, and identify several antiviral drugs ready for clinical trials.To sum up:An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.The research shows how the virus shifts the cell’s activity to promote its own...
-
Document de presse | 2022.10.30
Institut Pasteur Welcomes New, Comprehensive Relationship With UCSF QBI
Two Academic and Scientific Heavyweights Agree to Implement Joint Actions Towards the Creation of a Center of Excellence in Emerging Infectious Diseases with Planned Operations/Locations in Paris and San Francisco. In a ceremony on October 21, 2022, the Institut Pasteur and UC San Francisco Quantitative Biosciences Institute (UCSF QBI) announced a new partnership for the joint establishment...
